Kura Oncology (KURA) News Today → Shocking $16T Elon Musk Crypto Leak (From Crypto 101 Media) (Ad) Free KURA Stock Alerts $22.17 -0.81 (-3.52%) (As of 05/17/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 19 at 1:56 PM | msn.comInvestor Enthusiasm Soars for Kura Oncology (NASDAQ:KURA)May 19 at 6:38 AM | americanbankingnews.comKura Oncology (NASDAQ:KURA) Earns "Market Outperform" Rating from JMP SecuritiesMay 19 at 2:36 AM | americanbankingnews.comKura Oncology, Inc. (NASDAQ:KURA) Receives Consensus Rating of "Moderate Buy" from BrokeragesMay 19 at 2:36 AM | marketbeat.comKura Oncology, Inc. (NASDAQ:KURA) Receives Average Rating of "Moderate Buy" from AnalystsKura Oncology, Inc. (NASDAQ:KURA - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the seven analysts that are covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a hold rating and six have issued a buy rating on the companMay 16 at 3:24 PM | markets.businessinsider.comBuy Rating Affirmed for Kura Oncology Amidst Positive Developments and Strong Trial ProgressMay 16 at 1:27 PM | marketbeat.comKura Oncology (NASDAQ:KURA) Stock Rating Reaffirmed by JMP SecuritiesJMP Securities reissued a "market outperform" rating and set a $32.00 price target on shares of Kura Oncology in a report on Thursday.May 16 at 10:23 AM | markets.businessinsider.comBuy Rating Affirmed for Kura Oncology Amidst Promising Ziftomenib Trials and Strategic AdvantagesMay 16 at 5:16 AM | americanbankingnews.comHC Wainwright Reiterates Buy Rating for Kura Oncology (NASDAQ:KURA)May 14, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Kura Oncology (KURA) and Tourmaline Bio (TRML)May 14, 2024 | marketbeat.comKura Oncology (NASDAQ:KURA) Stock Rating Reaffirmed by HC WainwrightHC Wainwright reiterated a "buy" rating and set a $32.00 price target on shares of Kura Oncology in a report on Tuesday.May 14, 2024 | globenewswire.comKura Oncology Completes Enrollment in Registration-Directed Trial of Ziftomenib in NPM1-Mutant AMLMay 8, 2024 | globenewswire.comKura Oncology to Participate in Bank of America Securities Healthcare ConferenceMay 7, 2024 | seekingalpha.comKura Oncology: Balancing Act Of Promise And PragmatismMay 6, 2024 | finance.yahoo.comKura Oncology, Inc. (NASDAQ:KURA) Q1 2024 Earnings Call TranscriptMay 6, 2024 | marketbeat.comJMP Securities Reiterates Market Outperform Rating for Kura Oncology (NASDAQ:KURA)JMP Securities reissued a "market outperform" rating and issued a $32.00 price target on shares of Kura Oncology in a report on Monday.May 3, 2024 | finanznachrichten.deKura Oncology, Inc.: Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 3, 2024 | chron.comKura Oncology: Q1 Earnings SnapshotMay 3, 2024 | finance.yahoo.comKura Oncology Inc (KURA) (Q1 2024) Earnings Call Transcript Highlights: Key Financial and ...May 3, 2024 | markets.businessinsider.comBuy Rating Affirmed for Kura Oncology Amid Strong Financials and Promising Clinical MilestonesMay 3, 2024 | marketbeat.comKura Oncology's (KURA) "Buy" Rating Reiterated at HC WainwrightHC Wainwright reissued a "buy" rating and set a $32.00 price objective on shares of Kura Oncology in a research report on Friday.May 3, 2024 | marketbeat.comKura Oncology (NASDAQ:KURA) Posts Quarterly Earnings Results, Misses Estimates By $0.03 EPSKura Oncology (NASDAQ:KURA - Get Free Report) announced its quarterly earnings data on Thursday. The company reported ($0.59) earnings per share for the quarter, missing analysts' consensus estimates of ($0.56) by ($0.03). During the same period in the previous year, the company posted ($0.50) EPS. The firm's revenue was up .0% on a year-over-year basis.May 3, 2024 | globenewswire.comKura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 2, 2024 | investorplace.comKURA Stock Earnings: Kura Oncology Misses EPS for Q1 2024May 2, 2024 | msn.comKura Oncology Q1 2024 Earnings PreviewMay 2, 2024 | finance.yahoo.comKura Oncology Reports First Quarter 2024 Financial ResultsMay 2, 2024 | globenewswire.comKura Oncology Reports First Quarter 2024 Financial ResultsApril 26, 2024 | marketbeat.comKura Oncology (KURA) Scheduled to Post Quarterly Earnings on ThursdayKura Oncology (NASDAQ:KURA) will be releasing earnings after the market closes on Thursday, May 2, Zacks reports.April 25, 2024 | globenewswire.comKura Oncology to Report First Quarter 2024 Financial ResultsApril 24, 2024 | uk.investing.comFDA grants breakthrough status for Kura Oncology's AML drug candicateApril 23, 2024 | finanznachrichten.deKura Oncology, Inc.: Kura Oncology Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AMLApril 22, 2024 | markets.businessinsider.comKura Oncology’s Buy Rating Affirmed by Analyst Joseph Pantginis Amid Breakthrough Therapy Designation and Promising Preclinical DataApril 22, 2024 | marketbeat.comKura Oncology (NASDAQ:KURA) Rating Reiterated by HC WainwrightHC Wainwright restated a "buy" rating and set a $32.00 price objective on shares of Kura Oncology in a research note on Monday.April 22, 2024 | marketbeat.comKura Oncology (NASDAQ:KURA) Shares Gap Up to $17.53Kura Oncology (NASDAQ:KURA) Shares Gap Up to $17.53April 22, 2024 | markets.businessinsider.comKura Oncology Gets FDA Breakthrough Therapy Designation For Ziftomenib In R/R NPM1-Mutant AMLApril 22, 2024 | marketwatch.comKura Oncology Gets Breakthrough Designation For Leukemia TherapyApril 22, 2024 | finance.yahoo.comKura Oncology Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AMLApril 15, 2024 | marketbeat.comStockNews.com Downgrades Kura Oncology (NASDAQ:KURA) to SellStockNews.com lowered Kura Oncology from a "hold" rating to a "sell" rating in a research report on Monday.April 15, 2024 | marketbeat.comDekaBank Deutsche Girozentrale Buys 65,000 Shares of Kura Oncology, Inc. (NASDAQ:KURA)DekaBank Deutsche Girozentrale raised its stake in Kura Oncology, Inc. (NASDAQ:KURA - Free Report) by 216.7% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 95,000 shares of the company's stock after purchasing an additional 65,000 shares during the quarter.April 11, 2024 | marketbeat.comVanguard Group Inc. Increases Stock Holdings in Kura Oncology, Inc. (NASDAQ:KURA)Vanguard Group Inc. lifted its stake in shares of Kura Oncology, Inc. (NASDAQ:KURA - Free Report) by 7.5% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 3,924,448 shares of the company's stock after buying an additional 275,173 shares durApril 10, 2024 | msn.comImmunotherapy After Definitive Therapy Flops in Head and Neck CancerApril 10, 2024 | nasdaq.comValidea Detailed Fundamental Analysis - KURAApril 10, 2024 | globenewswire.comKura Oncology to Participate in Stifel Targeted Oncology ForumApril 10, 2024 | globenewswire.comKura Oncology to Participate in Stifel Targeted Oncology ForumApril 5, 2024 | globenewswire.comKura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 3, 2024 | marketbeat.comKura Oncology (NASDAQ:KURA) Upgraded to "Hold" by StockNews.comStockNews.com upgraded shares of Kura Oncology from a "sell" rating to a "hold" rating in a research note on Wednesday.March 28, 2024 | markets.businessinsider.comStifel Nicolaus Reaffirms Their Buy Rating on Celcuity (CELC)March 20, 2024 | marketbeat.comKura Oncology (NASDAQ:KURA) Shares Gap Down to $21.69Kura Oncology (NASDAQ:KURA) Shares Gap Down to $21.69March 17, 2024 | marketbeat.comWalleye Capital LLC Buys 182,221 Shares of Kura Oncology, Inc. (NASDAQ:KURA)Walleye Capital LLC lifted its stake in Kura Oncology, Inc. (NASDAQ:KURA - Free Report) by 220.4% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 264,893 shares of the company's stock after acquiring an additional 182,March 12, 2024 | marketbeat.comTrexquant Investment LP Reduces Stake in Kura Oncology, Inc. (NASDAQ:KURA)Trexquant Investment LP trimmed its stake in Kura Oncology, Inc. (NASDAQ:KURA - Free Report) by 55.9% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 36,715 shares of the company's stock after sellinMarch 7, 2024 | marketbeat.comKura Oncology (NASDAQ:KURA) Hits New 1-Year High at $23.75Kura Oncology (NASDAQ:KURA) Reaches New 1-Year High at $23.75 Get Kura Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for KURA and its competitors with MarketBeat's FREE daily newsletter. Email Address POTUS in ‘25 Not Biden/Trump, But (Ad)And I believe when they do take the oath of office, their fingers will be crossed… and America will descend into chaos. Click here now to see my urgent election warning. KURA Media Mentions By Week KURA Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. KURA News Sentiment▼0.400.42▲Average Medical News Sentiment KURA News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. KURA Articles This Week▼134▲KURA Articles Average Week Get Kura Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for KURA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: SUPN News TARO News SYRE News RCUS News EWTX News LGND News GPCR News SDGR News HRMY News AVDL News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:KURA) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersForget Bitcoin: This $8 Stock Is the Next Big ThingBehind the MarketsBuy this small stock before coming AI Tidal WaveChaikin AnalyticsCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingShocking $16T Elon Musk Crypto LeakCrypto 101 MediaHow Biden has already won 2024Porter & CompanyExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersUrgent Nvidia WarningAltimetry41 banks launch ‘crypto dollar’Stansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kura Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
